Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Clin Cancer Res. 2011 Nov 16;18(1):127–139. doi: 10.1158/1078-0432.CCR-11-1889

Figure 3.

Figure 3

Figure 3

Figure 3

Figure 3

Figure 3

SOCS2 expression negatively regulates STAT3 activation. (A–B) TU167 and Osc19 cells were mock-transfected with no siRNA, nontargeting (scrambled), or SOCS2-specific siRNA (KD, knockdown). Cells were subjected to no further treatment (A) or incubated with 100 nM dasatinib for 30 minutes before lysis (B) and then harvested and lysed. The indicated molecules were visualized using Western blot analysis. (C) TU167 and Osc19 cell lines were transiently transfected with the pMet7-FLAG -mSOCS2 overexpression construct (SOCS2 OE) or vector control. Cells were harvested and lysed 72 hours after transfection, and the indicated molecules were analyzed by Western blot analysis. TU167 (D) and Osc19 (E) cells were transfected with SOCS2 OE. Cells were treated with 100 nM dasatinib for the indicated times starting 48 hours after transfection, lysed, and analyzed by Western blot analysis.